Genes Associated With Prognosis After Surgery For Malignant Pleural Mesothelioma Promote Tumor Cell Survival In Vitro

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Gordon, Gavin J ^a   Bueno, Raphael ^a   Sugarbaker, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Genes polymorphisms; Genetics genomics; Mesothelioma Cell biology culture

Indexed keywords

ARHGDIA PROTEIN; CELL SURFACE PROTEIN; COBLL1 PROTEIN; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; PKM2 PROTEIN; PYRUVATE KINASE; REGULATOR PROTEIN; SMALL INTERFERING RNA; TM4SF1 PROTEIN; UNCLASSIFIED DRUG; MEMBRANE ANTIGEN; TM4SF1 PROTEIN, HUMAN; TUMOR PROTEIN;

APOPTOSIS; ARHGDIA GENE; ARTICLE; CELL SURVIVAL; COBLL1 GENE; CONTROLLED STUDY; GENETIC ASSOCIATION; HUMAN; IN VITRO STUDY; MITOSIS; NUCLEAR SIZE; PKM2 GENE; PLEURA MESOTHELIOMA; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TM4SF1 GENE; TUMOR CELL; CELL PROLIFERATION; GENE SILENCING; GENETICS; MESOTHELIOMA; METABOLISM; PATHOLOGY; PHENOTYPE; PLEURA TUMOR; TUMOR CELL LINE;

ANTIGENS, SURFACE; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; MESOTHELIOMA; MITOSIS; NEOPLASM PROTEINS; PHENOTYPE; PLEURAL NEOPLASMS; PROGNOSIS; RNA INTERFERENCE;

EID: 79955876338     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-169     Document Type: Article

References (43)

1. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999, 79(3-4):666-672. 2362439, 10027347.
2. Murayama Y, Miyagawa J, Shinomura Y, Kanayama S, Isozaki K, Yamamori K, Mizuno H, Ishiguro S, Kiyohara T, Miyazaki Y, et al. Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 2002, 98(4):505-513. 10.1002/ijc.10198, 11920609.
3. Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T, Chan CC, Wen CP, Furuya S, Higashi T, et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 2007, 369(9564):844-849. 10.1016/S0140-6736(07)60412-7, 17350453.
4. Aisner J. Diagnosis, staging, and natural history of pleural mesothelioma. Comprehensive Textbook of Thoracic Oncology 1996, 799-785. Baltimore: Williams and Wilkins, Aisner J, AR, Green MR, Martini N, Perry MC.
5. Bignon J, Brochard P, Pairon JC. Mesothelioma: causes and fiber-related mechanisms. Comprehensive Textbook of Thoracic Oncology 1996, 735-756. Baltimore: Williams and Wilkins, AisneR J, Arriagada R, Green M, Martini N, Perry M.
6. Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur Respir J 1998, 12(4):972-981. 10.1183/09031936.98.12040972, 9817178.
7. Corson JM, Renshaw AA. Pathology of mesothelioma. Comprehensive Textbook of Thoracic Oncology 1996, 757-758. Baltimore: Williams and Wilkins, AisneR J, Arriagada R, Green MR, Martini N, Perry MC.
8. Kindler HL, Vogelzang NJ. Mesothelioma. Oncologic Therapies 1999, 635-651. Berlin: Springer-Verlag, Vokes EE, Golomb HM.
9. Cury PM, Butcher DN, Corrin B, Nicholson AG. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 1999, 189(2):251-257. 10.1002/(SICI)1096-9896(199910)189:2<251::AID-PATH412>3.0.CO;2-F, 10547583.
10. Sugarbaker DJ, Norberto JJ, Bueno R. Current Therapy for Mesothelioma. Cancer Control 1997, 4(4):326-334.
11. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644. 10.1200/JCO.2003.11.136, 12860938.
12. Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 2005, 19(6):1117-1136. vii, 10.1016/j.hoc.2005.09.010, 16325127.
13. Sugarbaker DJ, Norberto JJ, Swanson SJ. Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997, 9(4):373-382.
14. Baldini EH, Recht A, Strauss GM, DeCamp MM, Swanson SJ, Liptay MJ, Mentzer SJ, Sugarbaker DJ. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997, 63(2):334-338. 10.1016/S0003-4975(96)01228-3, 9033296.
15. Flores RM. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 2005, 49(Suppl 1):S71-74.
16. Flores RM, Routledge T, Seshan VE, Dycoco J, Zakowski M, Hirth Y, Rusch VW. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 2008, 136(3):605-610. 10.1016/j.jtcvs.2008.02.069, 18805259.
17. Richards WG, Zellos L, Bueno R, Jaklitsch MT, Janne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006, 24(10):1561-1567. 10.1200/JCO.2005.04.6813, 16575008.
18. Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, Bueno R, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009, 138(2):405-411. 10.1016/j.jtcvs.2009.02.046, 19619785.
19. Zellos L, Richards WG, Capalbo L, Jaklitsch MT, Chirieac LR, Johnson BE, Bueno R, Sugarbaker DJ. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2009, 137(2):453-458. 10.1016/j.jtcvs.2008.07.055, 19185169.
20. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Richards WG, Jaklitsch MT, Sugarbaker DJ, Bueno R. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003, 95(8):598-605. 10.1093/jnci/95.8.598, 12697852.
21. Gordon GJ, Rockwell GN, Godfrey PA, Jensen RV, Glickman JN, Yeap BY, Richards WG, Sugarbaker DJ, Bueno R. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2005, 11(12):4406-4414. 10.1158/1078-0432.CCR-04-2181, 1488818, 15958625.
22. Gordon GJ, Dong L, Yeap BY, Richards WG, Glickman JN, Edenfield H, Mani M, Colquitt R, Maulik G, Van Oss B, et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst 2009, 101(9):678-686. 10.1093/jnci/djp061, 2677573, 19401544.
23. Carpenter AE, Sabatini DM. Systematic genome-wide screens of gene function. Nat Rev Genet 2004, 5(1):11-22.
24. Echeverri CJ, Perrimon N. High-throughput RNAi screening in cultured cells: a user's guide. Nat Rev Genet 2006, 7(5):373-384.
25. Sachse C, Weiss-Haljiti C, Holz C, Regener K, Halley F, al E. Exploring the full power of combining high throughput RNAi with high content readouts: from target discovery screens to drug modifier studies. High Content Screening: Science, Techniques and Applications 2008, 145-168. Hoboken: John Wiley & Sons, SA H.
26. Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, Downward J, Ellenberg J, Fraser AG, Hacohen N, et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 2006, 3(10):777-779. 10.1038/nmeth1006-777, 16990807.
27. Broers JL, Bronnenberg NM, Kuijpers HJ, Schutte B, Hutchison CJ, Ramaekers FC. Partial cleavage of A-type lamins concurs with their total disintegration from the nuclear lamina during apoptosis. Eur J Cell Biol 2002, 81(12):677-691. 10.1078/0171-9335-00282, 12553668.
28. Oriuchi N, Higuchi T, Hanaoka H, Iida Y, Endo K. Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med 2005, 19(5):355-365. 10.1007/BF03027399, 16164191.
29. Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, Chu YW, Yang PC, Wu CW, Roffler SR. Tumor-associated antigen L6 and the invasion of human lung cancer cells. Clin Cancer Res 2003, 9(7):2807-2816.
30. Shih SC, Zukauskas A, Li D, Liu G, Ang LH, Nagy JA, Brown LF, Dvorak HF. The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis. Cancer Res 2009, 69(8):3272-3277. 10.1158/0008-5472.CAN-08-4886, 2774109, 19351819.
31. Nagase T, Ishikawa K, Suyama M, Kikuno R, Hirosawa M, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O. Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res 1999, 6(1):63-70. 10.1093/dnares/6.1.63, 10231032.
32. Carroll EA, Gerrelli D, Gasca S, Berg E, Beier DR, Copp AJ, Klingensmith J. Cordon-bleu is a conserved gene involved in neural tube formation. Dev Biol 2003, 262(1):16-31. 10.1016/S0012-1606(03)00323-3, 14512015.
33. Leffers H, Nielsen MS, Andersen AH, Honore B, Madsen P, Vandekerckhove J, Celis JE. Identification of two human Rho GDP dissociation inhibitor proteins whose overexpression leads to disruption of the actin cytoskeleton. Exp Cell Res 1993, 209(2):165-174. 10.1006/excr.1993.1298, 8262133.
34. Turner SJ, Zhuang S, Zhang T, Boss GR, Pilz RB. Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors. Biochem Pharmacol 2008, 75(2):405-413. 10.1016/j.bcp.2007.08.031, 2228324, 17920041.
35. El Marzouk S, Schultz-Norton JR, Likhite VS, McLeod IX, Yates JR, Nardulli AM. Rho GDP dissociation inhibitor alpha interacts with estrogen receptor alpha and influences estrogen responsiveness. J Mol Endocrinol 2007, 39(4):249-259. 10.1677/JME-07-0055, 17909265.
36. Su LF, Knoblauch R, Garabedian MJ. Rho GTPases as modulators of the estrogen receptor transcriptional response. J Biol Chem 2001, 276(5):3231-3237. 10.1074/jbc.M005547200, 11060289.
37. Zhao L, Wang H, Li J, Liu Y, Ding Y. Overexpression of Rho GDP-dissociation inhibitor alpha is associated with tumor progression and poor prognosis of colorectal cancer. J Proteome Res 2008, 7(9):3994-4003. 10.1021/pr800271b, 18651761.
38. Atsushi T, Jun M, Hiroyoshi I, Miki T, Ayumi T, al E. Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDI alpha. Oncogene 1999, 18(39):5373-5380. 10.1038/sj.onc.1202921, 10498891.
39. Park YJ, Ahn HJ, Chang HK, Kim JY, Huh KH, Kim MS, Kim YS. The RhoGDI-alpha/JNK signaling pathway plays a significant role in mycophenolic acid-induced apoptosis in an insulin-secreting cell line. Cell Signal 2009, 21(2):356-364. 10.1016/j.cellsig.2008.11.009, 19041939.
40. Vander Heiden MG, Christofk HR, Schuman E, Subtelny AO, Sharfi H, Harlow EE, Xian J, Cantley LC. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 2010, 79(8):1118-1124. 10.1016/j.bcp.2009.12.003, 2823991, 20005212.
41. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005, 15(4):300-308. 10.1016/j.semcancer.2005.04.009, 15908230.
42. Cao X, Littlejohn J, Rodarte C, Zhang L, Martino B, Rascoe P, Hamid K, Jupiter D, Smythe WR. Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. Am J Pathol 2009, 175(5):2207-2216. 10.2353/ajpath.2009.090070, 2774082, 19834061.
43. Fennell DA, Rudd RM. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 2004, 5(6):354-362. 10.1016/S1470-2045(04)01492-5, 15172356.